BR9713126A - Compostos derivados da piridin-2-il-metilamina, processo para sua preparação, compostos intermediários de sìntese, medicamento inédito, e, composição farmacêutica - Google Patents

Compostos derivados da piridin-2-il-metilamina, processo para sua preparação, compostos intermediários de sìntese, medicamento inédito, e, composição farmacêutica

Info

Publication number
BR9713126A
BR9713126A BR9713126-1A BR9713126A BR9713126A BR 9713126 A BR9713126 A BR 9713126A BR 9713126 A BR9713126 A BR 9713126A BR 9713126 A BR9713126 A BR 9713126A
Authority
BR
Brazil
Prior art keywords
represents hydrogen
compounds
methyl
fluorine
pct
Prior art date
Application number
BR9713126-1A
Other languages
English (en)
Other versions
BR9713126B1 (pt
Inventor
Bernard Vacher
Bernard Bonnaud
Wouter Koek
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR9713126A publication Critical patent/BR9713126A/pt
Publication of BR9713126B1 publication Critical patent/BR9713126B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

"COMPOSTOS DERIVADOS DA PIRIDIN-2-IL-METILAMINA PROCESSO PARA SUA PREPARAçãO, COMPOSTOS INTERMEDIáRIOS DE SìNTESE, MEDICAMENTO INéDITO, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a novos derivados da piridin-2-il-metilamina de fórmula (I) em que: u representa um átomo de hidrogênio ou um radical metila; v representa um átomo de hidrogênio ou um átomo de cloro ou um radical metila; w representa um átomo de hidrogênio ou um átomo de flúor ou um radical metila; x representa um átomo de hidrogênio ou um átomo de flúor: y representa um átomo de cloro ou um radical metila; z representa um átomo de hidrogênio ou um átomo de flúor ou um átomo de cloro ou um radical metila; A representa: um átomo de hidrogênio ou um átomo de flúor ou um átomo de cloro; um radical alquila com C~ 1~-C~ 5~, um radical fluoroalquila; um radical ciclopropila; um grupo heterocíclico aromático com 5 membros de cadeia; um grupo alcóxi ou alquiltio; um grupo amino; um grupo amino cíclico; um grupo alcoxicarbonila. Estes compostos são úteis como medicamentos, principalmente como antidepressivos e analgésicos.
BRPI9713126-1A 1996-11-21 1997-11-20 compostos derivados da piridin-2-il-metilamina, processo para sua preparaÇço, compostos intermediÁrios de sÍntese, uso de um composto, e, composiÇço farmacÊutica. BR9713126B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614217A FR2755967B1 (fr) 1996-11-21 1996-11-21 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
PCT/FR1997/002097 WO1998022459A1 (fr) 1996-11-21 1997-11-20 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
BR9713126A true BR9713126A (pt) 2000-04-11
BR9713126B1 BR9713126B1 (pt) 2009-01-13

Family

ID=9497861

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713126-1A BR9713126B1 (pt) 1996-11-21 1997-11-20 compostos derivados da piridin-2-il-metilamina, processo para sua preparaÇço, compostos intermediÁrios de sÍntese, uso de um composto, e, composiÇço farmacÊutica.

Country Status (14)

Country Link
US (1) US6020345A (pt)
EP (1) EP0946546B1 (pt)
JP (1) JP4248605B2 (pt)
CN (1) CN1098263C (pt)
AT (1) ATE243691T1 (pt)
AU (1) AU732470B2 (pt)
BR (1) BR9713126B1 (pt)
CA (1) CA2272460C (pt)
DE (1) DE69723104T2 (pt)
DK (1) DK0946546T3 (pt)
ES (1) ES2202647T3 (pt)
FR (1) FR2755967B1 (pt)
PT (1) PT946546E (pt)
WO (1) WO1998022459A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US8106074B2 (en) * 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
ES2393900T3 (es) * 2001-12-03 2012-12-28 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
PT1580188E (pt) * 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
KR100435105B1 (ko) * 2002-04-17 2004-06-09 금호석유화학 주식회사 카르복시이미데이트 리간드에 기초한 원자이동 라디칼중합을 이용한 새로운 메틸메타아크릴레이트의 중합방법
FR2840900B1 (fr) * 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
FR2852244B1 (fr) * 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
ATE366108T1 (de) * 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) * 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
WO2012145617A2 (en) * 2011-04-22 2012-10-26 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
HUE037945T2 (hu) 2014-07-09 2018-09-28 Pf Medicament Eljárás mozgási rendellenességek kezelésére befiradollal
EP3260452A1 (en) 2016-06-24 2017-12-27 Neurolixis Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
WO2018057576A1 (en) 2016-09-22 2018-03-29 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
EP3664787B1 (en) 2017-07-20 2022-07-20 Neurolixis Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
EP0661266A1 (en) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists

Also Published As

Publication number Publication date
US6020345A (en) 2000-02-01
PT946546E (pt) 2003-11-28
CA2272460C (fr) 2009-11-17
CN1098263C (zh) 2003-01-08
WO1998022459A1 (fr) 1998-05-28
BR9713126B1 (pt) 2009-01-13
DE69723104D1 (de) 2003-07-31
AU5227698A (en) 1998-06-10
CN1242772A (zh) 2000-01-26
FR2755967B1 (fr) 1999-01-29
AU732470B2 (en) 2001-04-26
ATE243691T1 (de) 2003-07-15
EP0946546A1 (fr) 1999-10-06
DK0946546T3 (da) 2003-10-20
ES2202647T3 (es) 2004-04-01
DE69723104T2 (de) 2004-04-29
EP0946546B1 (fr) 2003-06-25
JP2001504129A (ja) 2001-03-27
JP4248605B2 (ja) 2009-04-02
FR2755967A1 (fr) 1998-05-22
CA2272460A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
BR9713126A (pt) Compostos derivados da piridin-2-il-metilamina, processo para sua preparação, compostos intermediários de sìntese, medicamento inédito, e, composição farmacêutica
PT958296E (pt) Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
DE69725608D1 (de) Indolin-2-one derivate, verfahren zu ihrer herstellung und dieseenthaltende arzneimittel
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
DK1414439T3 (da) Nye pyrroler med hypolipidæmiske og hypocholesterolæmiske aktiviteter, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem og deres anvendelse indenfor medicin
NO953844L (no) 1-amidinofenyl-pyrrolidoner piperidinoner azetinoner som plateaggregeringshemmere
ATE411294T1 (de) 4-amino-azepan-3-on-derivate als protease- inhibitors
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
AR004961A1 (es) Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
DK0994854T3 (da) Fremgangsmåde til fremstilling af en substitueret perhydroisoindol
ES2154830T3 (es) Derivados de 2-aminolactama n-(4-bencilo sustituida).
DK0891341T3 (da) 1,3,4-Oxadiazinderivater samt deres anvendelse som pesticider
ATE311384T1 (de) Eine amidgruppe tragende schwefelhaltige verbindungen, verfahren zu ihrer herstellung, deren verwendung in medikamenten und sie enthaltende pharmazeutische zubereitungen
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
DK1525188T3 (da) Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
NO995685D0 (no) Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasöytiske blandinger
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE172454T1 (de) Pyridazinon derivate mit pharmazeutischer wirkung
DK1257552T3 (da) Xanthinderivater, mellemprodukter og anvendelse til behandling af osteoporose
NO992870D0 (no) Difenylalkyl-tetrahydropyridiner, fremgangsmÕter for deres fremstilling og farmas°ytiske blandinger inneholdende dem
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/02/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 25.02.2019